4//SEC Filing
Yen Yun 4
Accession 0001493152-21-016038
CIK 0001335105other
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 4:06 PM ET
Size
10.5 KB
Accession
0001493152-21-016038
Insider Transaction Report
Form 4
Yen Yun
Director
Transactions
- Award
Options to Purchase Common Stock
2021-06-30+100,000→ 100,000 totalExercise: $3.03From: 2021-06-30Exp: 2026-06-30→ Common (100,000 underlying)
Holdings
- 52,632(indirect: By Sino-American Cancer FDD)
Warrants to Purchase Common Stock
Exercise: $5.70From: 2020-11-30Exp: 2025-11-30→ Common (52,632 underlying) - 50,000
Options to Purchase Common Stock
Exercise: $3.21From: 2021-01-06Exp: 2026-01-06→ Common (50,000 underlying) - 33,333
Options to Purchase Common Stock
Exercise: $1.68From: 2018-08-04Exp: 2023-08-04→ Common (33,333 underlying) - 8,333
Options to Purchase Common Stock
Exercise: $6.60From: 2019-05-22Exp: 2024-05-22→ Common (8,333 underlying)
Footnotes (1)
- [F1]Effective June 30, 2021, the reporting person was granted stock options to purchase an aggregate of 100,000 shares, vesting in eight equal installments on the last day of each subsequent quarter until fully vested (e.g. vesting to start on September 20, 2021).
Documents
Issuer
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
CIK 0001335105
Entity typeother
Related Parties
1- filerCIK 0001684584
Filing Metadata
- Form type
- 4
- Filed
- Jul 1, 8:00 PM ET
- Accepted
- Jul 2, 4:06 PM ET
- Size
- 10.5 KB